PureTech Health PLC Notice of Results (0604Z)
August 29 2018 - 2:01AM
UK Regulatory
TIDMPRTC
RNS Number : 0604Z
PureTech Health PLC
29 August 2018
29 August 2018
PureTech Health plc
Notice of Half-Yearly Results
PureTech Health plc (LSE: PRTC), an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis, expects to announce its half-yearly
results for the six months ended 30 June 2018 at 7.00am BST on
Tuesday 11 September 2018.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep insight
into the connection between the individual components of these
systems and the resulting role in many chronic diseases, which
represent the majority of healthcare spend and have proven
resistant to established therapeutic approaches. By harnessing this
emerging field of human biology, PureTech Health is developing new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions: the Affiliates division and the
Internal division. Its Affiliates division includes two product
candidates that are preparing for potential regulatory approval in
the United States and Europe as well as other novel clinical and
pre-clinical programmes. These affiliates are developing
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading experts.
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. These programmes
leverage the transport and biodistribution of various immune system
components for the targeted treatment of diseases with major unmet
needs, including cancers, autoimmune diseases, and neuroimmune
disorders.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
Investors EU Media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBCGDIDSDBGII
(END) Dow Jones Newswires
August 29, 2018 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024